We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Trovagene's Liquid Biopsy to Participate in Precision Promise
Read MoreHide Full Article
San Diego, CA-based Trovagene Inc. , a molecular diagnostic company, has been recently selected as the liquid biopsy provider for a study named Precision Promise. The study is a large-scale precision medical trial to treat pancreatic cancer patients.
Leading non-profit organization The Pancreatic Cancer Action Network is expected to make an initial investment of $35 million toward this effort.
Coming to share price movement, Trovagene surged 4.5% to close at $4.58 per share, highly justifying the development. However, a further analysis shows bearish market trends as Trovagene represents a negative year-to-date return of 15.2%, way lower than the S&P 500’s 5.2% over the same time frame.
Notably, the company’s flagship Trovera liquid biopsy test will be used in the study. With the latest development, Trovagene is expected to enhance the clinical trial process for treating pancreatic cancer, the third leading cause of cancer-related deaths in the U.S.
Per management, the latest development is likely to fortify the company’s market position by validating the company’s flagship quantitative liquid biopsy testing procedures.
The global liquid biopsy market by cancer type is expected to reach a worth of $1.66 billion by 2021, growing at a CAGR of 23.4% (Markets and Markets). Such bullish prospects are expected to propel growth for Trovagene in the coming quarters.
Of the other recent developments, Trovagene recently signed an ‘in-network provider agreement’ with Blue Cross Blue Shield of Illinois, a division of Health Care Service Corporation, which is likely to expand the company’s network. In fact, the publication of a study demonstrating clinical information of ‘Trovera urine liquid biopsy test’ platform in Experimental Hematology & Oncology, an open access journal, is also a significant positive in our view.
GW Pharmaceuticals has a solid year-to-date return of 91.7%, way better than the S&P 500’s 5.2% over the same time frame. Notably, the company posted a positive earnings surprise in the last four quarters, the average being 41.6%.
ABIOMED posted an impressive one-year return of 52.1%. The company recorded a positive earnings surprise in the last four quarters, the average being 34.9%
Quidel Corp. has a positive year-to-date return of 2%. The stock has a healthy expected earnings growth rate of 20%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Trovagene's Liquid Biopsy to Participate in Precision Promise
San Diego, CA-based Trovagene Inc. , a molecular diagnostic company, has been recently selected as the liquid biopsy provider for a study named Precision Promise. The study is a large-scale precision medical trial to treat pancreatic cancer patients.
Leading non-profit organization The Pancreatic Cancer Action Network is expected to make an initial investment of $35 million toward this effort.
Coming to share price movement, Trovagene surged 4.5% to close at $4.58 per share, highly justifying the development. However, a further analysis shows bearish market trends as Trovagene represents a negative year-to-date return of 15.2%, way lower than the S&P 500’s 5.2% over the same time frame.
Notably, the company’s flagship Trovera liquid biopsy test will be used in the study. With the latest development, Trovagene is expected to enhance the clinical trial process for treating pancreatic cancer, the third leading cause of cancer-related deaths in the U.S.
Per management, the latest development is likely to fortify the company’s market position by validating the company’s flagship quantitative liquid biopsy testing procedures.
TROVAGENE INC Price
TROVAGENE INC Price | TROVAGENE INC Quote
Our Take
The global liquid biopsy market by cancer type is expected to reach a worth of $1.66 billion by 2021, growing at a CAGR of 23.4% (Markets and Markets). Such bullish prospects are expected to propel growth for Trovagene in the coming quarters.
Of the other recent developments, Trovagene recently signed an ‘in-network provider agreement’ with Blue Cross Blue Shield of Illinois, a division of Health Care Service Corporation, which is likely to expand the company’s network. In fact, the publication of a study demonstrating clinical information of ‘Trovera urine liquid biopsy test’ platform in Experimental Hematology & Oncology, an open access journal, is also a significant positive in our view.
Key Picks
Trovagene holds a Zacks Rank #2 (Buy).
Otehr favorably ranked stocks in the broader medical sector are GW Pharmaceuticals Plc. , ABIOMED and Quidel Corp. (QDEL - Free Report) . All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
GW Pharmaceuticals has a solid year-to-date return of 91.7%, way better than the S&P 500’s 5.2% over the same time frame. Notably, the company posted a positive earnings surprise in the last four quarters, the average being 41.6%.
ABIOMED posted an impressive one-year return of 52.1%. The company recorded a positive earnings surprise in the last four quarters, the average being 34.9%
Quidel Corp. has a positive year-to-date return of 2%. The stock has a healthy expected earnings growth rate of 20%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>